Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan

This publication has 16 references indexed in Scilit:

• Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome
  JAMA Oncology, 2020
• Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017
  American Journal of Hematology, 2019
• Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia
  Transplantation and Cellular Therapy, 2019
• Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60–69 years with myelodysplastic syndrome
  Annals of Hematology, 2019
• HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis
  Transplantation and Cellular Therapy, 2019
• Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis
  Hematological Oncology, 2018
• Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
  Transplantation and Cellular Therapy, 2017
• Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
  New England Journal of Medicine, 2010
• Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
  Journal of Clinical Oncology, 2010
• Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
  Journal of Clinical Oncology, 2010